Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.39% | |
| New Downtrend | Bearish | 0.39% | |
| 50 DMA Support | Bullish | 0.39% | |
| Wide Range Bar | Range Expansion | 0.39% | |
| Multiple of Ten Bearish | Other | 0.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Inside Day | about 11 hours ago |
| Up 2% | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 12 hours ago |
| Rose Above Lower Bollinger Band | about 14 hours ago |
| Up 1% | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 02/27/2023
Supernus Pharmaceuticals, Inc. Description
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drug Discovery Clinical Trial Clinical Research Chloride Epilepsy Depression Neurology Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Disease Hyperactivity Disorder Investigational New Drug Treatment Of Depression Treatment Of Epilepsy Treatment Of Central Nervous System Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.09 |
| 52 Week Low | 24.96 |
| Average Volume | 383,241 |
| 200-Day Moving Average | 33.07 |
| 50-Day Moving Average | 38.19 |
| 20-Day Moving Average | 40.41 |
| 10-Day Moving Average | 40.62 |
| Average True Range | 1.21 |
| RSI | 40.83 |
| ADX | 30.72 |
| +DI | 17.71 |
| -DI | 27.43 |
| Chandelier Exit (Long, 3 ATRs) | 38.45 |
| Chandelier Exit (Short, 3 ATRs) | 41.00 |
| Upper Bollinger Bands | 42.63 |
| Lower Bollinger Band | 38.18 |
| Percent B (%b) | 0.02 |
| BandWidth | 11.00 |
| MACD Line | 0.49 |
| MACD Signal Line | 0.92 |
| MACD Histogram | -0.4322 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 40.66 | ||||
| Resistance 3 (R3) | 40.63 | 39.82 | 40.27 | ||
| Resistance 2 (R2) | 39.82 | 39.21 | 39.83 | 40.13 | |
| Resistance 1 (R1) | 39.05 | 38.84 | 39.44 | 39.08 | 40.00 |
| Pivot Point | 38.24 | 38.24 | 38.43 | 38.25 | 38.24 |
| Support 1 (S1) | 37.47 | 37.63 | 37.86 | 37.50 | 36.58 |
| Support 2 (S2) | 36.66 | 37.26 | 36.67 | 36.45 | |
| Support 3 (S3) | 35.89 | 36.66 | 36.32 | ||
| Support 4 (S4) | 35.92 |
